Carnexiv Dosage
Generic name: CARBAMAZEPINE 10mg in 1mL
Dosage form: injection, powder, for solution
Drug class: Dibenzazepine anticonvulsants
Medically reviewed by Drugs.com. Last updated on Jan 9, 2024.
2.1 Dosage Information
CARNEXIV is a replacement therapy for oral carbamazepine. Carbamazepine treatment should generally be initiated with an oral carbamazepine formulation.
The total daily dose of CARNEXIV is 70% of the total daily oral carbamazepine dose from which patients are being switched (see Table 1). The total daily dose of CARNEXIV should be equally divided in four 30-minute infusions, separated by 6 hours.
Patients should be switched back to oral carbamazepine administration at their previous total daily oral dose and frequency of administration as soon as clinically appropriate. The use of CARNEXIV for periods of more than 7 days has not been studied.
Table 1. Determination of Total Daily Dose for CARNEXIV Infusion
Total Daily Oral Carbamazepine Dose (mg/day)
|
Corresponding Total Daily Dose of CARNEXIV (mg/day) |
Dose of CARNEXIV to be administered every 6 hours (mg) |
400 |
280 |
70 |
600 |
420 |
105 |
800 |
560 |
140 |
1,000 |
700 |
175 |
1,200 |
840 |
210 |
1,400 |
980 |
245 |
1,600 |
1,120 |
280 |
2.2 Administration Information
CARNEXIV is for intravenous use only and must be diluted in a compatible diluent prior to infusion.
Using Table 2 as a guide, prepare the solution for each infusion by transferring the single dose volume of CARNEXIV to 100 mL of diluent solution (0.9% sodium chloride, lactated Ringer's solution, or 5% dextrose) and mixing gently.
Before administration, the prepared solution for infusion may be stored for a maximum of 4 hours at 20°C to 25°C (68°F to 77°F) or a maximum of 24 hours if refrigerated at 2°C to 8°C (36°F to 46°F).
Parenteral drug products should be inspected visually for particulate matter, cloudiness, or discoloration prior to administration, whenever solution and container permit. If any of these are present, discard the solution.
Administer each infusion intravenously over 30 minutes.
CARNEXIV injection vials are for single-dose only. Discard any unused portion.
Table 2. CARNEXIV Dose to Volume and Infusion Table
CARNEXIV Single Dose (mg/every 6 hours) |
CARNEXIV Single Dose Volume (Vials Required) |
Diluent Volume |
Infusion Duration |
Dose Frequency |
70 |
7 mL (1) |
100 mL
|
30 min
|
Every 6 hours |
105 |
10.5 mL (1) |
|||
140 |
14 mL (1) |
|||
175 |
17.5 mL (1) |
|||
210 |
21 mL (2) |
|||
245 |
24.5 mL (2) |
|||
280 |
28 mL (2) |
2.3 Renal Function Monitoring
Patients with renal impairment may be at greater risk for an adverse effect of CARNEXIV on renal function, and should have close monitoring of renal function during treatment with CARNEXIV. CARNEXIV should generally not be used in patients with moderate or severe renal impairment.
2.4 Serum Level Monitoring
Monitor serum carbamazepine concentrations in conditions in which alterations in carbamazepine metabolism can occur. This includes patients who have hepatic impairment and patients on drugs that either induce or inhibit carbamazepine metabolism.
2.5 Laboratory Testing Prior to Carbamazepine Initiation
Prior to initial treatment with carbamazepine, test patients with ancestry in genetically at-risk populations for the presence of the HLA-B*1502 allele. The high resolution genotype test is positive if one or two HLA-B*1502 alleles are present. Avoid use of CARNEXIV in patients testing positive for the allele, unless the benefit clearly outweighs the risk.
Complete pretreatment blood counts, including platelets and possibly reticulocytes and serum iron, should be obtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of CARNEXIV should be considered if any evidence of significant bone marrow depression develops.
Baseline and periodic evaluations of liver function, particularly in patients with a history of liver disease, must be performed during treatment with carbamazepine because liver damage may occur. Discontinue CARNEXIV in cases of aggravated liver dysfunction or active liver disease.
Frequently asked questions
More about Carnexiv (carbamazepine)
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- FDA approval history
- Drug class: dibenzazepine anticonvulsants
- Breastfeeding
Patient resources
Other brands
Tegretol, Tegretol XR, Carbatrol, Equetro, Epitol
Professional resources
Other brands
Tegretol, Carbatrol, Equetro, Epitol
Related treatment guides
See also:
Lyrica
Lyrica is used to control seizures, treat nerve pain and fibromyalgia. Learn about side effects ...
Depakote
Depakote is used to treat various types of seizure disorders. Learn about side effects ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Levetiracetam
Levetiracetam systemic is used for bipolar disorder, epilepsy, hyperekplexia, neuralgia, new daily ...
Lamictal
Lamictal is an anti-epileptic medication used treat seizures in adults and children over 2 years ...
Topiramate
Topiramate systemic is used for bipolar disorder, borderline personality disorder, bulimia ...
Diazepam
Diazepam is used to treat anxiety disorders, alcohol withdrawal symptoms, or muscle spasms. Learn ...
Pregabalin
Pregabalin may be used to treat certain types of pain and used in combination with other ...
Lorazepam
Lorazepam is in a group of drugs called benzodiazepines and is used to treat anxiety disorders ...
Clonazepam
Clonazepam is used to treat seizures and panic disorder. Learn about side effects, interactions and ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.